<DOC>
	<DOC>NCT01953692</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDAÂ®) in hematologic malignancies. The primary study hypotheses are that treatment with pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate (ORR) or Complete Remission Rate (CRR).</brief_summary>
	<brief_title>A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criteria: Has confirmed diagnosis of relapse or refractory Multiple Myeloma, Primary mediastinal Large B cell Lymphoma, nonHodgkin lymphoma (NHL), Follicular Lymphoma, Diffuse Large B cell lymphoma, Hodgkin lymphoma or Myelodysplastic syndrome. Has measureable disease Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale Demonstrates adequate organ function Prior therapy criteria must be met Is currently participating in and receiving study therapy or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study therapy Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years, has received a live vaccine within 30 days of planned start of study therapy, has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1, received a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered from adverse events due to a previously administered agent Has known clinically active central nervous system (CNS) involvement Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis Has evidence of interstitial lung disease, active noninfectious pneumonitis, a known additional malignancy that is progressing or requires active treatment, an active infection requiring intravenous systemic therapy, an active autoimmune disease that has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial Has received prior therapy with an antiprogrammed cell death 1 (antiPD1), antiprogrammed cell death ligand 1 (antiPDL1), antiPDL2, antiCD137, or antiCytotoxic Tlymphocyteassociated antigen4 (CTLA4) antibody (including ipilimumab or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways) Has known symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>